All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
24Jun20 07:00 RNS Scancell 0.93% Health £25.4m New publication highlights potential of Modi-1
12Jun20 09:30 RNS-R Scancell 0.93% Health £25.4m Publication highlights potential of AvidiMab
01May20 07:00 RNS Scancell 0.93% Health £25.4m Director salaries and award of share options
28Apr20 10:06 RNS Scancell 0.93% Health £25.4m Director Dealing
27Apr20 16:39 RNS Scancell 0.93% Health £25.4m Director Dealing
24Apr20 07:00 RNS Scancell 0.93% Health £25.4m Scancell: Development of vaccine against COVID-19
03Mar20 07:00 RNS-R Scancell 0.93% Health £25.4m Scancell to Present at Three Research Conferences
03Feb20 07:00 RNS Scancell 0.93% Health £25.4m SCIB1 IND Application Approved
31Jan20 07:00 RNS Scancell 0.93% Health £25.4m Interim Results
20Jan20 07:00 RNS Scancell 0.93% Health £25.4m Third agreement signed for antibody platform
17Dec19 12:44 RNS Scancell 0.93% Health £25.4m Director's Dealings
16Dec19 07:00 RNS Scancell 0.93% Health £25.4m Second agreement signed for AvidiMab platform
20Nov19 07:00 RNS Scancell 0.93% Health £25.4m New European Moditope patent allowed for grant
23Oct19 07:00 RNS Scancell 0.93% Health £25.4m Directorate Change
26Sep19 07:00 RNS Scancell 0.93% Health £25.4m Posters at Cancer Immunotherapy Conference
12Sep19 15:56 RNS Scancell 0.93% Health £25.4m Result of AGM
04Sep19 07:00 RNS Scancell 0.93% Health £25.4m First Collaboration Agreement for AvidiMab
20Aug19 14:23 RNS Scancell 0.93% Health £25.4m Notice of AGM
20Aug19 07:00 RNS Scancell 0.93% Health £25.4m Final Results for the year ended 30 April 2019
19Aug19 07:00 RNS Scancell 0.93% Health £25.4m Update on the SCIB1 Phase 2 clinical trial
07Aug19 07:00 RNS Scancell 0.93% Health £25.4m Notice of Final Results
01Jul19 07:00 RNS-R Scancell 0.93% Health £25.4m H1 2019 Business Update
18Jun19 09:16 RNS Hygea VCT 0.00% Various Various Holding(s) in Company
18Jun19 07:00 RNS Scancell 0.93% Health £25.4m Board Appointment
17Jun19 10:45 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
13Jun19 07:00 RNS Scancell 0.93% Health £25.4m Share Subscription and Issue of Equity to Vulpes
20May19 07:00 RNS-R Scancell 0.93% Health £25.4m Scancell and CRUK provide an update on SCIB2
10May19 07:00 RNS-R Scancell 0.93% Health £25.4m Clinical Advisory Board and Update on Modi-1
25Apr19 07:00 RNS Scancell 0.93% Health £25.4m UK approval to start SCIB1 Phase 2 trial
08Apr19 07:00 RNS-R Scancell 0.93% Health £25.4m Japan patent for Moditope immunotherapy platform
21Mar19 07:00 RNS-R Scancell 0.93% Health £25.4m Professor Lindy Durrant receives Waldenström award
20Mar19 07:00 RNS Scancell 0.93% Health £25.4m Scancell strengthens IP portfolio
05Mar19 18:27 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
21Feb19 07:00 RNS Scancell 0.93% Health £25.4m Change of Auditor
31Jan19 07:00 RNS Scancell 0.93% Health £25.4m Interim Results
23Jan19 07:00 RNS-R Scancell 0.93% Health £25.4m Update on Cancer Research UK's Grand Challenge
21Jan19 07:00 RNS-R Scancell 0.93% Health £25.4m Appoints Heads of Research and Manufacturing
12Nov18 07:00 RNS-R Scancell 0.93% Health £25.4m Scancell to Present at Two Conferences
01Nov18 07:00 RNS-R Scancell 0.93% Health £25.4m Scancell to present at Proactive Investors Forum
30Oct18 17:18 RNS Scancell 0.93% Health £25.4m Results of AGM
30Oct18 07:00 RNS Scancell 0.93% Health £25.4m Identification of 2nd Moditope Cancer Vaccine
24Oct18 07:00 RNS Scancell 0.93% Health £25.4m Update on SCIB1 Phase 2 Clinical Study
05Oct18 07:00 RNS Scancell 0.93% Health £25.4m Notice of AGM
25Sep18 07:00 RNS Scancell 0.93% Health £25.4m Final Results for the year ended 30 April 2018
18Sep18 07:00 RNS Scancell 0.93% Health £25.4m Notice of Final Results
10Aug18 07:00 RNS Scancell 0.93% Health £25.4m Board Change
09Aug18 07:00 RNS Scancell 0.93% Health £25.4m Agreement
25Jul18 14:45 RNS Scancell 0.93% Health £25.4m Director/PDMR Shareholding
24Jul18 07:00 RNS Scancell 0.93% Health £25.4m Issue of Equity
18Jul18 07:00 RNS Scancell 0.93% Health £25.4m Scancell exercises TriGrid commercial option
11May18 13:11 RNS Legal & General Group 0.73% Various Various Holding(s) in Company
09May18 10:12 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
08May18 07:00 RNS Scancell 0.93% Health £25.4m Result of the Open Offer and PDMR Shareholdings
23Apr18 12:43 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
20Apr18 16:32 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
18Apr18 14:29 RNS Scancell 0.93% Health £25.4m Result of Placing and Subscription and PDMR
18Apr18 07:00 RNS Scancell 0.93% Health £25.4m Proposed Placing, Subscription and Open Offer
15Feb18 07:00 RNS Scancell 0.93% Health £25.4m Collaboration agreement with ISA Pharmaceuticals
12Feb18 07:00 RNS Scancell 0.93% Health £25.4m Publication highlights potential of SCIB1 therapy
09Feb18 07:00 RNS Scancell 0.93% Health £25.4m European patent application allowed for grant
01Feb18 07:00 RNS Scancell 0.93% Health £25.4m Director/PDMR Shareholding
30Jan18 07:00 RNS Scancell 0.93% Health £25.4m Half-year Report
09Jan18 07:00 RNS Scancell 0.93% Health £25.4m Scancell to collaborate with BioNTech
14Dec17 07:00 RNS Scancell 0.93% Health £25.4m Scancell and CRUK to advance cancer immunotherapy
11Oct17 09:44 RNS Scancell 0.93% Health £25.4m Result of AGM
10Oct17 07:00 RNS Scancell 0.93% Health £25.4m Directorate Change
14Sep17 07:00 RNS Scancell 0.93% Health £25.4m Notice of AGM
13Sep17 07:00 RNS Scancell 0.93% Health £25.4m Final Results
11Jul17 07:00 RNS Scancell 0.93% Health £25.4m Continued Progress on SCIB1
22May17 12:59 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
19May17 14:47 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
19May17 07:00 RNS Legal & General Group 0.73% Various Various Holding(s) in Company
11May17 12:09 RNS Scancell 0.93% Health £25.4m Results of Placing
11May17 07:00 RNS Scancell 0.93% Health £25.4m Proposed Placing to Raise up to £5.0 million
01Mar17 07:00 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
31Jan17 07:00 RNS Scancell 0.93% Health £25.4m Interim Results
30Jan17 07:00 RNS Scancell 0.93% Health £25.4m Partnership to Advance Lung Cancer Clinical Trials
03Jan17 11:33 RNS Scancell 0.93% Health £25.4m Research Update - Amendment
03Jan17 07:00 RNS Scancell 0.93% Health £25.4m Research Update
18Oct16 17:42 RNS Scancell 0.93% Health £25.4m Results of AGM
10Oct16 07:00 RNS Scancell 0.93% Health £25.4m Preparing SCIB2 for clinical study in lung cancer
23Sep16 17:24 RNS Scancell 0.93% Health £25.4m Notice of AGM - Amendment
23Sep16 15:28 RNS Scancell 0.93% Health £25.4m Notice of AGM
16Sep16 07:00 RNS Scancell 0.93% Health £25.4m Final Results
22Aug16 07:00 RNS Scancell 0.93% Health £25.4m Appointment of Non-Executive Director
21Jul16 07:00 RNS Scancell 0.93% Health £25.4m Eurogentec manufacturing agreement
20Jul16 07:00 RNS Scancell 0.93% Health £25.4m Extension to Ichor Commercial Option
06Jul16 07:00 RNS Scancell 0.93% Health £25.4m SCIB1 compelling survival data in melanoma
17Jun16 07:00 RNS Scancell 0.93% Health £25.4m SCIB1 Drug Product Supply
18May16 07:00 RNS Scancell 0.93% Health £25.4m Opens US Headquarters in San Diego
19Apr16 07:00 RNS Scancell 0.93% Health £25.4m Director/PDMR Shareholding
11Apr16 16:11 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
06Apr16 07:00 RNS Scancell 0.93% Health £25.4m Holding(s) in Company
04Apr16 10:17 RNS Scancell 0.93% Health £25.4m Result of the open offer
01Apr16 07:00 RNS Scancell 0.93% Health £25.4m Result of open offer
11Mar16 07:00 RNS Scancell 0.93% Health £25.4m Posting of Circular
11Mar16 07:00 RNS Scancell 0.93% Health £25.4m Strategic collaboration with Karolinska Institutet
09Mar16 14:07 RNS Scancell 0.93% Health £25.4m Placing and Open Offer Close
09Mar16 07:00 RNS Scancell 0.93% Health £25.4m Proposed Placing and Open Offer
27Jan16 09:00 RNS Scancell 0.93% Health £25.4m Amendment to Options
Date / Time Source Company % Chg
24Jun20 07:00 RNS Scancell 0.93%
New publication highlights potential of Modi-1
12Jun20 09:30 RNS-R Scancell 0.93%
Publication highlights potential of AvidiMab
01May20 07:00 RNS Scancell 0.93%
Director salaries and award of share options
28Apr20 10:06 RNS Scancell 0.93%
Director Dealing
27Apr20 16:39 RNS Scancell 0.93%
Director Dealing
24Apr20 07:00 RNS Scancell 0.93%
Scancell: Development of vaccine against COVID-19
03Mar20 07:00 RNS-R Scancell 0.93%
Scancell to Present at Three Research Conferences
03Feb20 07:00 RNS Scancell 0.93%
SCIB1 IND Application Approved
31Jan20 07:00 RNS Scancell 0.93%
Interim Results
20Jan20 07:00 RNS Scancell 0.93%
Third agreement signed for antibody platform
17Dec19 12:44 RNS Scancell 0.93%
Director's Dealings
16Dec19 07:00 RNS Scancell 0.93%
Second agreement signed for AvidiMab platform
20Nov19 07:00 RNS Scancell 0.93%
New European Moditope patent allowed for grant
23Oct19 07:00 RNS Scancell 0.93%
Directorate Change
26Sep19 07:00 RNS Scancell 0.93%
Posters at Cancer Immunotherapy Conference
12Sep19 15:56 RNS Scancell 0.93%
Result of AGM
04Sep19 07:00 RNS Scancell 0.93%
First Collaboration Agreement for AvidiMab
20Aug19 14:23 RNS Scancell 0.93%
Notice of AGM
20Aug19 07:00 RNS Scancell 0.93%
Final Results for the year ended 30 April 2019
19Aug19 07:00 RNS Scancell 0.93%
Update on the SCIB1 Phase 2 clinical trial
07Aug19 07:00 RNS Scancell 0.93%
Notice of Final Results
01Jul19 07:00 RNS-R Scancell 0.93%
H1 2019 Business Update
18Jun19 09:16 RNS Hygea VCT 0.00%
Holding(s) in Company
18Jun19 07:00 RNS Scancell 0.93%
Board Appointment
17Jun19 10:45 RNS Scancell 0.93%
Holding(s) in Company
13Jun19 07:00 RNS Scancell 0.93%
Share Subscription and Issue of Equity to Vulpes
20May19 07:00 RNS-R Scancell 0.93%
Scancell and CRUK provide an update on SCIB2
10May19 07:00 RNS-R Scancell 0.93%
Clinical Advisory Board and Update on Modi-1
25Apr19 07:00 RNS Scancell 0.93%
UK approval to start SCIB1 Phase 2 trial
08Apr19 07:00 RNS-R Scancell 0.93%
Japan patent for Moditope immunotherapy platform
21Mar19 07:00 RNS-R Scancell 0.93%
Professor Lindy Durrant receives Waldenström award
20Mar19 07:00 RNS Scancell 0.93%
Scancell strengthens IP portfolio
05Mar19 18:27 RNS Scancell 0.93%
Holding(s) in Company
21Feb19 07:00 RNS Scancell 0.93%
Change of Auditor
31Jan19 07:00 RNS Scancell 0.93%
Interim Results
23Jan19 07:00 RNS-R Scancell 0.93%
Update on Cancer Research UK's Grand Challenge
21Jan19 07:00 RNS-R Scancell 0.93%
Appoints Heads of Research and Manufacturing
12Nov18 07:00 RNS-R Scancell 0.93%
Scancell to Present at Two Conferences
01Nov18 07:00 RNS-R Scancell 0.93%
Scancell to present at Proactive Investors Forum
30Oct18 17:18 RNS Scancell 0.93%
Results of AGM
30Oct18 07:00 RNS Scancell 0.93%
Identification of 2nd Moditope Cancer Vaccine
24Oct18 07:00 RNS Scancell 0.93%
Update on SCIB1 Phase 2 Clinical Study
05Oct18 07:00 RNS Scancell 0.93%
Notice of AGM
25Sep18 07:00 RNS Scancell 0.93%
Final Results for the year ended 30 April 2018
18Sep18 07:00 RNS Scancell 0.93%
Notice of Final Results
10Aug18 07:00 RNS Scancell 0.93%
Board Change
09Aug18 07:00 RNS Scancell 0.93%
Agreement
25Jul18 14:45 RNS Scancell 0.93%
Director/PDMR Shareholding
24Jul18 07:00 RNS Scancell 0.93%
Issue of Equity
18Jul18 07:00 RNS Scancell 0.93%
Scancell exercises TriGrid commercial option
11May18 13:11 RNS Legal & General Group 0.73%
Holding(s) in Company
09May18 10:12 RNS Scancell 0.93%
Holding(s) in Company
08May18 07:00 RNS Scancell 0.93%
Result of the Open Offer and PDMR Shareholdings
23Apr18 12:43 RNS Scancell 0.93%
Holding(s) in Company
20Apr18 16:32 RNS Scancell 0.93%
Holding(s) in Company
18Apr18 14:29 RNS Scancell 0.93%
Result of Placing and Subscription and PDMR
18Apr18 07:00 RNS Scancell 0.93%
Proposed Placing, Subscription and Open Offer
15Feb18 07:00 RNS Scancell 0.93%
Collaboration agreement with ISA Pharmaceuticals
12Feb18 07:00 RNS Scancell 0.93%
Publication highlights potential of SCIB1 therapy
09Feb18 07:00 RNS Scancell 0.93%
European patent application allowed for grant
01Feb18 07:00 RNS Scancell 0.93%
Director/PDMR Shareholding
30Jan18 07:00 RNS Scancell 0.93%
Half-year Report
09Jan18 07:00 RNS Scancell 0.93%
Scancell to collaborate with BioNTech
14Dec17 07:00 RNS Scancell 0.93%
Scancell and CRUK to advance cancer immunotherapy
11Oct17 09:44 RNS Scancell 0.93%
Result of AGM
10Oct17 07:00 RNS Scancell 0.93%
Directorate Change
14Sep17 07:00 RNS Scancell 0.93%
Notice of AGM
13Sep17 07:00 RNS Scancell 0.93%
Final Results
11Jul17 07:00 RNS Scancell 0.93%
Continued Progress on SCIB1
22May17 12:59 RNS Scancell 0.93%
Holding(s) in Company
19May17 14:47 RNS Scancell 0.93%
Holding(s) in Company
19May17 07:00 RNS Legal & General Group 0.73%
Holding(s) in Company
11May17 12:09 RNS Scancell 0.93%
Results of Placing
11May17 07:00 RNS Scancell 0.93%
Proposed Placing to Raise up to £5.0 million
01Mar17 07:00 RNS Scancell 0.93%
Holding(s) in Company
31Jan17 07:00 RNS Scancell 0.93%
Interim Results
30Jan17 07:00 RNS Scancell 0.93%
Partnership to Advance Lung Cancer Clinical Trials
03Jan17 11:33 RNS Scancell 0.93%
Research Update - Amendment
03Jan17 07:00 RNS Scancell 0.93%
Research Update
18Oct16 17:42 RNS Scancell 0.93%
Results of AGM
10Oct16 07:00 RNS Scancell 0.93%
Preparing SCIB2 for clinical study in lung cancer
23Sep16 17:24 RNS Scancell 0.93%
Notice of AGM - Amendment
23Sep16 15:28 RNS Scancell 0.93%
Notice of AGM
16Sep16 07:00 RNS Scancell 0.93%
Final Results
22Aug16 07:00 RNS Scancell 0.93%
Appointment of Non-Executive Director
21Jul16 07:00 RNS Scancell 0.93%
Eurogentec manufacturing agreement
20Jul16 07:00 RNS Scancell 0.93%
Extension to Ichor Commercial Option
06Jul16 07:00 RNS Scancell 0.93%
SCIB1 compelling survival data in melanoma
17Jun16 07:00 RNS Scancell 0.93%
SCIB1 Drug Product Supply
18May16 07:00 RNS Scancell 0.93%
Opens US Headquarters in San Diego
19Apr16 07:00 RNS Scancell 0.93%
Director/PDMR Shareholding
11Apr16 16:11 RNS Scancell 0.93%
Holding(s) in Company
06Apr16 07:00 RNS Scancell 0.93%
Holding(s) in Company
04Apr16 10:17 RNS Scancell 0.93%
Result of the open offer
01Apr16 07:00 RNS Scancell 0.93%
Result of open offer
11Mar16 07:00 RNS Scancell 0.93%
Posting of Circular
11Mar16 07:00 RNS Scancell 0.93%
Strategic collaboration with Karolinska Institutet
09Mar16 14:07 RNS Scancell 0.93%
Placing and Open Offer Close
09Mar16 07:00 RNS Scancell 0.93%
Proposed Placing and Open Offer
27Jan16 09:00 RNS Scancell 0.93%
Amendment to Options
Date / Time Company % Chg
24Jun20 07:00 Scancell 0.93%
New publication highlights potential of Modi-1
12Jun20 09:30 Scancell 0.93%
Publication highlights potential of AvidiMab
01May20 07:00 Scancell 0.93%
Director salaries and award of share options
28Apr20 10:06 Scancell 0.93%
Director Dealing
27Apr20 16:39 Scancell 0.93%
Director Dealing
24Apr20 07:00 Scancell 0.93%
Scancell: Development of vaccine against COVID-19
03Mar20 07:00 Scancell 0.93%
Scancell to Present at Three Research Conferences
03Feb20 07:00 Scancell 0.93%
SCIB1 IND Application Approved
31Jan20 07:00 Scancell 0.93%
Interim Results
20Jan20 07:00 Scancell 0.93%
Third agreement signed for antibody platform
17Dec19 12:44 Scancell 0.93%
Director's Dealings
16Dec19 07:00 Scancell 0.93%
Second agreement signed for AvidiMab platform
20Nov19 07:00 Scancell 0.93%
New European Moditope patent allowed for grant
23Oct19 07:00 Scancell 0.93%
Directorate Change
26Sep19 07:00 Scancell 0.93%
Posters at Cancer Immunotherapy Conference
12Sep19 15:56 Scancell 0.93%
Result of AGM
04Sep19 07:00 Scancell 0.93%
First Collaboration Agreement for AvidiMab
20Aug19 14:23 Scancell 0.93%
Notice of AGM
20Aug19 07:00 Scancell 0.93%
Final Results for the year ended 30 April 2019
19Aug19 07:00 Scancell 0.93%
Update on the SCIB1 Phase 2 clinical trial
07Aug19 07:00 Scancell 0.93%
Notice of Final Results
01Jul19 07:00 Scancell 0.93%
H1 2019 Business Update
18Jun19 09:16 HYG LSE,SCLP LSE 0.00%
Holding(s) in Company
18Jun19 07:00 Scancell 0.93%
Board Appointment
17Jun19 10:45 Scancell 0.93%
Holding(s) in Company
13Jun19 07:00 Scancell 0.93%
Share Subscription and Issue of Equity to Vulpes
20May19 07:00 Scancell 0.93%
Scancell and CRUK provide an update on SCIB2
10May19 07:00 Scancell 0.93%
Clinical Advisory Board and Update on Modi-1
25Apr19 07:00 Scancell 0.93%
UK approval to start SCIB1 Phase 2 trial
08Apr19 07:00 Scancell 0.93%
Japan patent for Moditope immunotherapy platform
21Mar19 07:00 Scancell 0.93%
Professor Lindy Durrant receives Waldenström award
20Mar19 07:00 Scancell 0.93%
Scancell strengthens IP portfolio
05Mar19 18:27 Scancell 0.93%
Holding(s) in Company
21Feb19 07:00 Scancell 0.93%
Change of Auditor
31Jan19 07:00 Scancell 0.93%
Interim Results
23Jan19 07:00 Scancell 0.93%
Update on Cancer Research UK's Grand Challenge
21Jan19 07:00 Scancell 0.93%
Appoints Heads of Research and Manufacturing
12Nov18 07:00 Scancell 0.93%
Scancell to Present at Two Conferences
01Nov18 07:00 Scancell 0.93%
Scancell to present at Proactive Investors Forum
30Oct18 17:18 Scancell 0.93%
Results of AGM
30Oct18 07:00 Scancell 0.93%
Identification of 2nd Moditope Cancer Vaccine
24Oct18 07:00 Scancell 0.93%
Update on SCIB1 Phase 2 Clinical Study
05Oct18 07:00 Scancell 0.93%
Notice of AGM
25Sep18 07:00 Scancell 0.93%
Final Results for the year ended 30 April 2018
18Sep18 07:00 Scancell 0.93%
Notice of Final Results
10Aug18 07:00 Scancell 0.93%
Board Change
09Aug18 07:00 Scancell 0.93%
Agreement
25Jul18 14:45 Scancell 0.93%
Director/PDMR Shareholding
24Jul18 07:00 Scancell 0.93%
Issue of Equity
18Jul18 07:00 Scancell 0.93%
Scancell exercises TriGrid commercial option
11May18 13:11 LGEN LSE,SCLP LSE 0.73%
Holding(s) in Company
09May18 10:12 Scancell 0.93%
Holding(s) in Company
08May18 07:00 Scancell 0.93%
Result of the Open Offer and PDMR Shareholdings
23Apr18 12:43 Scancell 0.93%
Holding(s) in Company
20Apr18 16:32 Scancell 0.93%
Holding(s) in Company
18Apr18 14:29 Scancell 0.93%
Result of Placing and Subscription and PDMR
18Apr18 07:00 Scancell 0.93%
Proposed Placing, Subscription and Open Offer
15Feb18 07:00 Scancell 0.93%
Collaboration agreement with ISA Pharmaceuticals
12Feb18 07:00 Scancell 0.93%
Publication highlights potential of SCIB1 therapy
09Feb18 07:00 Scancell 0.93%
European patent application allowed for grant
01Feb18 07:00 Scancell 0.93%
Director/PDMR Shareholding
30Jan18 07:00 Scancell 0.93%
Half-year Report
09Jan18 07:00 Scancell 0.93%
Scancell to collaborate with BioNTech
14Dec17 07:00 Scancell 0.93%
Scancell and CRUK to advance cancer immunotherapy
11Oct17 09:44 Scancell 0.93%
Result of AGM
10Oct17 07:00 Scancell 0.93%
Directorate Change
14Sep17 07:00 Scancell 0.93%
Notice of AGM
13Sep17 07:00 Scancell 0.93%
Final Results
11Jul17 07:00 Scancell 0.93%
Continued Progress on SCIB1
22May17 12:59 Scancell 0.93%
Holding(s) in Company
19May17 14:47 Scancell 0.93%
Holding(s) in Company
19May17 07:00 LGEN LSE,SCLP LSE 0.73%
Holding(s) in Company
11May17 12:09 Scancell 0.93%
Results of Placing
11May17 07:00 Scancell 0.93%
Proposed Placing to Raise up to £5.0 million
01Mar17 07:00 Scancell 0.93%
Holding(s) in Company
31Jan17 07:00 Scancell 0.93%
Interim Results
30Jan17 07:00 Scancell 0.93%
Partnership to Advance Lung Cancer Clinical Trials
03Jan17 11:33 Scancell 0.93%
Research Update - Amendment
03Jan17 07:00 Scancell 0.93%
Research Update
18Oct16 17:42 Scancell 0.93%
Results of AGM
10Oct16 07:00 Scancell 0.93%
Preparing SCIB2 for clinical study in lung cancer
23Sep16 17:24 Scancell 0.93%
Notice of AGM - Amendment
23Sep16 15:28 Scancell 0.93%
Notice of AGM
16Sep16 07:00 Scancell 0.93%
Final Results
22Aug16 07:00 Scancell 0.93%
Appointment of Non-Executive Director
21Jul16 07:00 Scancell 0.93%
Eurogentec manufacturing agreement
20Jul16 07:00 Scancell 0.93%
Extension to Ichor Commercial Option
06Jul16 07:00 Scancell 0.93%
SCIB1 compelling survival data in melanoma
17Jun16 07:00 Scancell 0.93%
SCIB1 Drug Product Supply
18May16 07:00 Scancell 0.93%
Opens US Headquarters in San Diego
19Apr16 07:00 Scancell 0.93%
Director/PDMR Shareholding
11Apr16 16:11 Scancell 0.93%
Holding(s) in Company
06Apr16 07:00 Scancell 0.93%
Holding(s) in Company
04Apr16 10:17 Scancell 0.93%
Result of the open offer
01Apr16 07:00 Scancell 0.93%
Result of open offer
11Mar16 07:00 Scancell 0.93%
Posting of Circular
11Mar16 07:00 Scancell 0.93%
Strategic collaboration with Karolinska Institutet
09Mar16 14:07 Scancell 0.93%
Placing and Open Offer Close
09Mar16 07:00 Scancell 0.93%
Proposed Placing and Open Offer
27Jan16 09:00 Scancell 0.93%
Amendment to Options